NRx and Israel Developing Covid-19 Vaccine to Attack Variants

Written By Steve Grabenheimer

Aug.30 -- NRx Pharmaceuticals CEO Dr. Jonathan Javitt says they are working with Israel on a Covid-19 vaccine that targets Covid variants. He says vaccines from last year are becoming less effective. He's on "Bloomberg Markets."

Steve Grabenheimer https://www.covspect.com
Previous

Infectious diseases expert: 'Zero COVID is not a reasonable proposition medium to long term'
Next

Vaccines Are Less Effective Against Delta—And Pfizer’s Protection Wanes Rapidly—But Are The Best Way To Protect Against Covid, Large Study Finds